RemeGen Co., Ltd. Enhances Governance with New Remuneration Committee

An update from RemeGen Co. Ltd. Class H ( (HK:9995) ) is now available.

RemeGen Co., Ltd. has established a Remuneration and Appraisal Committee to enhance its corporate governance and remuneration management system. This committee is responsible for evaluating and recommending remuneration strategies and policies for directors and senior management, as well as overseeing performance appraisals and incentive schemes. The committee’s recommendations, once approved by the Board, will be presented for consideration at the shareholders’ meeting. This move is expected to strengthen the company’s governance and align its management’s incentives with corporate goals, potentially impacting its market positioning positively.

The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.

More about RemeGen Co. Ltd. Class H

RemeGen Co., Ltd. is a company involved in the pharmaceutical industry, focusing on the development and commercialization of innovative biologic drugs. The company is committed to enhancing its corporate governance structure and establishing a sound remuneration management system.

Average Trading Volume: 9,367,111

Technical Sentiment Signal: Buy

Current Market Cap: HK$31.81B

For detailed information about 9995 stock, go to TipRanks’ Stock Analysis page.